MAM
Kotak Mutual Fund awards creative duties to Everest Brand Solutions
MUMBAI: Creative agency Everest Brand Solutions, which is going through a phase of transformation, has won the creative duties of Kotak Mutual Fund for an undisclosed amount.
The company awarded the business to the agency based on the strategy and creative work presented by them.
Everest Brand Solutions president Dhunji S. Wadia said, “We believe in working with our clients and adding value to their business. More and more clients are recognising what we bring to the table. It‘s a huge vote of confidence for our way of working. This is a significant win for us.”
Everest NCD Rahul Jauhari said, “Our point of view on what Kotak Mutual Fund should do given the turbulent times in the market found favour with the Kotak team. It‘s an exciting category as well. We look forward to a long and fruitful relationship.”
Speaking on the agency‘s new drive, Wadia said, “Everest is in an exciting phase of transformation. The hard work put in over the last few months is bearing fruit now. We expect a lot of action in the coming months.”
The agency currently has accounts of companies like Danone Blue, Ranbaxy Volini, GoAir, Augere’s Wireless Broadband.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
